Oral Oncology Reports最新文献_第7页

Erratum regarding previously published article 关于以前发表的文章的勘误

Oral Oncology Reports Pub Date : 2024-12-01 DOI: 10.1016/j.oor.2023.100136

引用次数: 0

HPV status and staging in oropharyngeal carcinoma: A review of recent AJCC/UICC revisions 口咽癌的HPV状态和分期：近期AJCC/UICC修订的回顾

Oral Oncology Reports Pub Date : 2024-11-29 DOI: 10.1016/j.oor.2024.100694

Madhan Krishnan , Sharan Basappa , Shyamaladevi Babu , Sandhya P

{"title":"HPV status and staging in oropharyngeal carcinoma: A review of recent AJCC/UICC revisions","authors":"Madhan Krishnan , Sharan Basappa , Shyamaladevi Babu , Sandhya P","doi":"10.1016/j.oor.2024.100694","DOIUrl":"10.1016/j.oor.2024.100694","url":null,"abstract":"<div><div>The incidence of oropharyngeal carcinoma (OPC) has been rising, particularly among HPV-positive patients, prompting a reevaluation of clinical staging practices. Recent revisions to the AJCC/UICC staging systems have recognized the distinct biological behavior associated with HPV-positive tumors, highlighting the necessity for tailored staging criteria that better reflect their unique prognostic characteristics. This review discusses the implications of HPV status on the clinical staging of oropharyngeal carcinoma, focusing on how these revisions influence prognosis and treatment strategies. The differential outcomes observed between HPV-positive and HPV-negative patients necessitate a more nuanced approach to management, advocating for personalized treatment plans that consider the specific tumor biology. Additionally, we explore the ongoing research efforts aimed at further refining staging criteria, including the identification of relevant biomarkers and the integration of advanced imaging techniques. As our understanding of HPV's role in cancer biology continues to evolve, it is imperative that our approaches to staging and management adapt accordingly. Ultimately, these revisions and the accompanying research will contribute to improved patient outcomes and more effective therapeutic interventions in the increasingly prevalent landscape of oropharyngeal carcinoma.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"13 ","pages":"Article 100694"},"PeriodicalIF":0.0,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143145776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Assessment of cancer associated fibroblasts amongst different histological variants of oral squamous cell carcinoma 口腔鳞状细胞癌不同组织学变异中癌相关成纤维细胞的评估

Oral Oncology Reports Pub Date : 2024-11-29 DOI: 10.1016/j.oor.2024.100696

Reshma Poothakulath Krishnan , Deepak Pandiar , Pratibha Ramani , Neha Kannan , Selvaraj Jayaraman

{"title":"Assessment of cancer associated fibroblasts amongst different histological variants of oral squamous cell carcinoma","authors":"Reshma Poothakulath Krishnan , Deepak Pandiar , Pratibha Ramani , Neha Kannan , Selvaraj Jayaraman","doi":"10.1016/j.oor.2024.100696","DOIUrl":"10.1016/j.oor.2024.100696","url":null,"abstract":"<div><h3>Background</h3><div>Cancer associated fibroblasts are heterogenous activated fibroblasts that form the central component of the tumor microenvironment. These cells influence the behavior of the tumor by activating various signaling pathways and initiating epithelial mesenchymal transition. CAFs have been reported in oral squamous cell carcinomas (OSCC), however, very few studies have evaluated the role of CAFs in different variants of OSCC. The aim of this study was to compare the role of CAFs in conventional OSCC and different variants of OSCCs.</div></div><div><h3>Materials and methods</h3><div>Eight each of well differentiated, moderately differentiated and poorly differentiated OSCC, 5 each of verrucous carcinoma and verrucous carcinoma turning into OSCC, three each of spindle cell carcinoma, basaloid OSCC and OSCC with clear cell differentiation and 2 cases of papillary OSCC were retrieved, and immunohistochemistry was performed with α-SMA to identify and evaluate the CAFs. Kaplan Meier analysis was carried out to evaluate the overall survival of the patients.</div></div><div><h3>Results</h3><div>Progressive increase in the CAF immunostaining was noted from papillary squamous cell carcinoma [mean - 1] to basaloid squamous cell carcinoma [1.6 ± 0.5] to spindle cell carcinoma and squamous cell carcinoma with clear cell changes [2.6 ± 0.5] (p = 0.00 - statistically significant). Patients with abundant CAF expression showed lesser survival rate when compared to patients with scanty or focal CAF immunohistochemical staining.</div></div><div><h3>Conclusion</h3><div>Increased CAF immunoexpression was noted in PDSCCs, VCs turning into SCC, OSCC with clear cell changes and spindle cell carcinoma. This highlights the aggressive nature of these tumors. Screening these tumor for the presence of CAFs will help in treatment planning and will aid in treatment planning and survival analysis.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"13 ","pages":"Article 100696"},"PeriodicalIF":0.0,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143145775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A fight against cancer with advancement of Schiff base metal complexes: Future prospects 希夫贱金属配合物与癌症的对抗：未来展望

Oral Oncology Reports Pub Date : 2024-11-26 DOI: 10.1016/j.oor.2024.100692

Monika Tyagi, Monika Dubey

引用次数: 0

Application of Bone Ring Technique (BRT) for 3D reconstruction in the anterior aesthetic zone after tumor surgery 骨环技术（BRT）在肿瘤术后前美学区三维重建中的应用

Oral Oncology Reports Pub Date : 2024-11-22 DOI: 10.1016/j.oor.2024.100684

Yan-Sheng Zeng , Peng-Yu Lai , Shan Shen

引用次数: 0

Resection of a left carotid body tumor in a young female patient: A case report 年轻女性患者左侧颈动脉体肿瘤切除术1例

Oral Oncology Reports Pub Date : 2024-11-22 DOI: 10.1016/j.oor.2024.100691

Anish P. Kamat , Abhishek Shukla , Mandar Deshpande

引用次数: 0

PD-L1 mediated immune escape in nasopharyngeal carcinoma: Impact of LMP1 and IFN-γ on immune surveillance 鼻咽癌中 PD-L1 介导的免疫逃逸：LMP1 和 IFN-γ 对免疫监视的影响

Oral Oncology Reports Pub Date : 2024-11-19 DOI: 10.1016/j.oor.2024.100688

Madhan Krishnan , Aruna Jothi shanmugam , Shyamaladevi Babu

{"title":"PD-L1 mediated immune escape in nasopharyngeal carcinoma: Impact of LMP1 and IFN-γ on immune surveillance","authors":"Madhan Krishnan , Aruna Jothi shanmugam , Shyamaladevi Babu","doi":"10.1016/j.oor.2024.100688","DOIUrl":"10.1016/j.oor.2024.100688","url":null,"abstract":"<div><div>Nasopharyngeal carcinoma (NPC) is a distinct malignancy in head and neck cancer, notably linked to Epstein-Barr virus (EBV) infections in regions with high prevalence. NPC's tumor microenvironment fosters immune escape mechanisms that support tumor cell survival, with programmed death-ligand 1 (PD-L1) as a key player. PD-L1 expression on NPC cells binds to the programmed death-1 (PD-1) receptor on T cells, thereby creating an immunosuppressive environment that impairs immune surveillance. Two significant modulators of PD-L1 expression in NPC include the EBV-encoded latent membrane protein 1 (LMP1) and the immune cytokine interferon-gamma (IFN-γ). Together, they contribute to the intricate regulation of PD-L1, enhancing immune evasion and complicating the landscape for effective treatment approaches. This review explores the molecular mechanisms underlying PD-L1 upregulation, focusing on LMP1's activation of the NF-κB and JAK/STAT pathways and IFN-γ′s paradoxical role in facilitating immune escape. Clinical evidence indicates that PD-L1 expression correlates with poor prognosis and resistance to standard therapies in NPC patients. Understanding these regulatory pathways may inform potential therapeutic strategies, including immune checkpoint inhibitors, combination therapies, and novel immune-based approaches tailored to NPC's unique etiology. By providing a comprehensive synthesis of existing studies, this review highlights the interplay between PD-L1, LMP1, and IFN-γ, offering a framework for innovative therapeutic strategies targeting immune escape mechanisms. Identifying patients most likely to benefit from immune-targeted approaches and leveraging combination treatments could improve outcomes for NPC patients facing advanced or resistant disease.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"12 ","pages":"Article 100688"},"PeriodicalIF":0.0,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142700695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Assessment of the mean dose of the pharyngeal constrictor muscles (as one organ) as a part of DARS and its effect on dysphagia in IMRT treated head and neck cancer patients 评估咽部收缩肌（作为一个器官）作为DARS的一部分的平均剂量及其对IMRT治疗头颈癌患者吞咽困难的影响

Oral Oncology Reports Pub Date : 2024-11-19 DOI: 10.1016/j.oor.2024.100689

May Gamal Ashour , Tarek Hamed Shouman , Ashraf Hamed Hassouna , Maha Hassan Mokhtar , Dalia Abdelfatah

{"title":"Assessment of the mean dose of the pharyngeal constrictor muscles (as one organ) as a part of DARS and its effect on dysphagia in IMRT treated head and neck cancer patients","authors":"May Gamal Ashour , Tarek Hamed Shouman , Ashraf Hamed Hassouna , Maha Hassan Mokhtar , Dalia Abdelfatah","doi":"10.1016/j.oor.2024.100689","DOIUrl":"10.1016/j.oor.2024.100689","url":null,"abstract":"<div><h3>Objective</h3><div>To assess the mean dose the pharyngeal constrictor muscle (PCM) received and its effect on dysphagia and develop a cut-off value for its occurrence.</div></div><div><h3>Methods</h3><div>116 patients with head and neck cancer who required bilateral neck irradiation treated using the simultaneous integrated boost IMRT technique were retrospectively evaluated. Pharyngeal constrictor (superior, middle, inferior) and cricopharyngeus and esophageal inlet muscles (cricopharyngeal inlet) were considered dysphagia/aspiration-related structures (DARS) and were summated as one organ at risk structure PCM. PlanPCM consists of the sum of one or multiple pharyngeal constrictor muscles away from high-risk volumes.</div></div><div><h3>Results</h3><div>This study enrolled 116 patients (37 female, 79 male), mean age of 51 years. The mean dose to PCM was 51.37 Gy ± SD (range, 30.08–63.86 Gy). The severity of dysphagia correlated significantly with the dose received by PlanPCM (p < 0.001). The mean dose to PlanPCM in the nasopharyngeal primary was 53.3 Gy (Range 44–63.5 Gy), while it was 45.4 Gy (Range 30.1–56.3 Gy) for laryngeal primaries. Our findings indicated that a dose exceeding 50 Gy to the PlanPCM was more likely associated with high occurrence of dysphagia at one year after the completion of treatment.</div></div><div><h3>Conclusion</h3><div>We reported that PCM delineation as a single structure with sparing the part outside the high risk volumes is more reproducible and leads to the same outcomes if delineated separately.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"13 ","pages":"Article 100689"},"PeriodicalIF":0.0,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143145771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Neoadjuvant immunotherapy in advanced oral cancer: Emerging treatment paradigms 晚期口腔癌的新辅助免疫疗法：新兴治疗范例

Oral Oncology Reports Pub Date : 2024-11-08 DOI: 10.1016/j.oor.2024.100683

Ankit Vishwani, Bipin Thomas Varghese, Shaji Thomas, Ashima Kumar, Japneet Kaur, Anukampa Sharma

{"title":"Neoadjuvant immunotherapy in advanced oral cancer: Emerging treatment paradigms","authors":"Ankit Vishwani, Bipin Thomas Varghese, Shaji Thomas, Ashima Kumar, Japneet Kaur, Anukampa Sharma","doi":"10.1016/j.oor.2024.100683","DOIUrl":"10.1016/j.oor.2024.100683","url":null,"abstract":"<div><h3>Background</h3><div>Locally advanced borderline resectable oral cancer poses significant treatment challenges due to its infiltrative nature and high relapse rates, leading to poor prognosis. Neoadjuvant immunotherapy may offer a novel therapeutic approach, potentially altering the standard of care for advanced oral cancer<strong>.</strong></div></div><div><h3>Case report</h3><div>Two patients with locally advanced tongue cancer, initially deemed inoperable, were treated with neoadjuvant immunotherapy. The first patient received 4 cycles of taxane, cisplatin, and pembrolizumab, while the second received 12 cycles of nivolumab and methotrexate. Both patients exhibited excellent clinical responses at the primary site and in regional lymph nodes. Following treatment, one patient underwent primary closure, and the other had a nasolabial flap with marginal mandibulectomy. Intraoperative frozen sections indicated tumor-free margins in both cases.</div></div><div><h3>Conclusion</h3><div>These two cases underscore the potential of neoadjuvant immunotherapy in managing borderline resectable oral squamous cell carcinoma (OSCC), initially deemed inoperable. The favorable outcomes highlight the need for more research and clinical trials to further assess the efficacy of this approach in head and neck cancers. In this review, we explore the scientific rationale, current clinical evidence, and key debated topics, including the evaluation of pathological and radiological responses.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"12 ","pages":"Article 100683"},"PeriodicalIF":0.0,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142653531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Epigenetic alterations in oral cancer: Mechanisms, biomarkers, and therapeutic targets 口腔癌的表观遗传学改变：机制、生物标记物和治疗目标

Oral Oncology Reports Pub Date : 2024-10-31 DOI: 10.1016/j.oor.2024.100681

Madhan Krishnan , Sharan Basappa , Shyamaladevi Babu

引用次数: 0